In This Section

Program

Please Note: All session times for the 13th AACR-JCA Joint Conference: From Cancer Discovery Science to Therapeutic Innovation are U.S. Hawaii–Aleutian Daylight (HDT).

Saturday, February 1

Sunday, February 2

Monday, February 3

Tuesday, February 4

Wednesday, February 5

Saturday, February 1

Registration

1-7 p.m. | Grand Promenade

Welcome and keynotes

6-7:30 p.m.

  • 6 p.m. | Welcome and Introduction of Keynote Speakers
  • 6:05 p.m. | Cancer trajectory in damaged tissues
    Hiroyuki Mano, National Cancer Center, Tokyo, Japan
  • 6:50 | Personalized cancer vaccines: Updates and encouraging results
    Catherine J. Wu, Dana-Farber Cancer Institute, Boston, Massachusetts

Opening reception

7:30-9 p.m. | Monarchy 5-7, Promenade

Sunday, February 2

Continental Breakfast and “networking Roundtables”

7-8 a.m. | Sunset Terrace

Plenary Session 1: Advances in Cancer Genomics

8-9:30 a.m. | Monarchy 1-4

  • 8 a.m. | Title to be announced
    Andrew Futreal, The University of Texas MD Anderson Cancer Center, Houston, Texas
  • 8:25 a.m. | Elucidating the pathogenesis of medulloblastoma through the discovery of novel genetic alterations
    Hiromichi Suzuki, National Cancer Center Japan, Kyoto, Japan
  • 8:50 a.m. | New functional genomics methods elucidate the cancer-specific transcriptome
    Yasuhiro Murakawa, Kyoto University, Kyoto, Japan
  • 9:15 | Anatomical genomic and transcriptomic analyses of Helicobacter pylori-driven gastric transformation*
    Yosuke Tanaka, National Cancer Center Research Institute, Tokyo, Japan

Break

9:30-10 a.m. | Grand Promenade

Plenary Session 2: Cancer Immune Interaction

10-11:30 a.m. | Monarchy 1-4

  • 10 a.m. | Immuno-genomic cancer evolution governs immune landscapes in the tumor microenvironment
    Hiroyoshi Nishikawa, Kyoto University, Kyoto, Japan
  • 10:25 a.m. | Title to be announced
    Elham Azizi, Columbia University, New York, New York
  • 10:50 a.m. | Toward new mechanisms to unleash targeted immune responses
    Livnat Jerby, Stanford University, Stanford, California
  • 11:15 a.m. | Spatial transcriptome profiling of multicellular dynamics in metastatic gastric cancers: Efficiency of immunotherapy plus vascular endothelial growth factor receptor 2 (VEGFR2) inhibition*
    Minae An, Samsung Medical Center, Seoul, South Korea

Free time

11:30 a.m.-4 p.m.

Plenary Session 3: Cancer Evolution and the Tumor Microenvironment

4-5:30 p.m. | Monarchy 1-4

  • 4 p.m. | Somatic mosaicism in non-cancer digestive epithelium
    Nobuyuki Kakiuchi, Kyoto University, Kyoto, Japan
  • 4:25 pm. | Title to be announced
    Sheila A. Stewart, Washington University in St. Louis, St. Louis, Missouri
  • 4:50 p.m. | Distinct tumor microenvironment phenotypes driven by cancer genotype in gastrointestinal cancer: Insights from mouse models and multi-omics analysis
     Yoku Hayakawa, The University of Tokyo, Tokyo, Japan
  • 5:15 p.m. | Multimodal spatial profiling reveals immune suppression and microenvironment remodeling in fallopian tube precursors to high-grade serous ovarian carcinoma*
    Tanjina Kader, Harvard Medical School, Boston, Massachusetts

poster session a

5:30-7:30 p.m. | Monarchy 5-7

Monday, February 3

Continental Breakfast and “Networking Roundtables”

7-8 a.m. | Sunset Terrace

Plenary Session 4: Genome Instability

8-9:30 a.m.

  • 8 a.m. | Title to be announced
    Ashok Venkitaraman, Cancer Science Institute of Singapore, Singapore
  • 8:25 a.m. | Title to be announced
    Ivana Bozic, University of Washington, Seattle, Washington
  • 8:50 a.m. | Dissecting the DNA damage response network
    Alberto Ciccia, Columbia University, New York, New York
  • 9:15 a.m. | Advancing precision medicine in pediatric sarcoma: Exploiting DNA damage response pathway for targeted therapies*
    Larissa Volken, Children’s Cancer Institute Australia, Sydney, Australia

Break

9:30-10 a.m. | Grand Promenade

Plenary Session 5: Cancer Plasticity and Resistance

10-11:30 a.m. | Monarchy 1-4

  • 10 a.m. | Title to be announced
    Laura D. Attardi, Stanford University, Stanford, California
  • 10:25 a.m. | Heterogeneous dormant breast cancer cells leverage bone marrow cell plasticity at the single-cell level to drive metastasis initiation
    Noriko Gotoh, Kanazawa University, Kanazawa, Japan
  • 10:50 a.m. | Title to be announced
    Tuomas Tammela, Memorial Sloan Kettering, New York, New York
  • 11:15 a.m. | Systematic interrogation of cancer cell states as drivers of environmental tolerance and therapy resistance in cancer*
    Srivatsan Raghavan, Dana-Farber Cancer Institute, Boston, Massachusetts

free time

11:30 a.m.-4 p.m.

Plenary Session 6: New Treatment Modalities

4-5:30 p.m. | Monarchy 1-4

  • 4 p.m. | Title to be announced
    Nathaneal S. Gray, Stanford University, Stanford, California
  • 4:25 p.m. | Epitope editing enables novel immunotherapies for acute myeloid leukemia
    Pietro Genovese, Dana-Farber Cancer Institute, Massachusetts
  • 4:50 p.m. | Title to be announced
    Mika Kamata-Sakurai, Chugai Pharmaceutical Co., Ltd., Tokyo, Japan
  • 5:15 p.m. | CRISPR/Cas9 knockout screen identifies SEMA3F gene for resistance to cyclin-dependent kinase 4 and 6 inhibitors in breast cancer*
    Yuko Kawai, Keio University School of Medicine, Tokyo, Japan

Poster session B

5:30-7:30 p.m. | Monarchy 1-4

Tuesday, February 4

Continental Breakfast and “Networking Roundtables”

7-8 a.m. | Sunset Terrace

Plenary Session 7: Cancer Metabolism

8-9:30 a.m. | Monarchy 1-4

  • 9 a.m. | Title to be announced
    Marcia C. Haigis, Harvard Medical School, Boston, Massachusetts
  • 9:25 a.m. | Fatty acid oxidation prevents active aldehyde accumulation and metabolic exhaustion in CD8+ T cells in tumor microenvironment
    Kenji Chamoto, Kyoto University, Kyoto, Japan
  • 9:50 a.m. | Metabolic reprogramming: A bridge between aging and cancer
    Ana P. Da Silva Gomes, H. Lee Moffitt Cancer Center, Tampa, Florida
  • 10:15 a.m. | Novel aneuploidy-associated therapeutic targets for squamous cell carcinoma*
    Nadja Zhakula-Kostadinova, Columbia University, New York, New York

Break

9:30-10 a.m. | Grand Promenade

Plenary Session 8: Population Sciences

10-11:30 a.m.

  • 10 a.m. | Molecular epidemiology studies of cancer risk, early detection, and prognosis
    Elizabeth A. Platz, Johns Hopkins University, Baltimore, Maryland
  • 10:30 a.m. | Integrative cancer population sciences to decipher the etiology of early-onset colorectal cancer
    Tomotaka Ugai, Harvard Medical School, Boston, Massachusetts
  • 11 a.m. | Bridging mechanisms and prevention: Insights from interactions
    Keitaro Matsuo, Aichi Cancer Center, Aichi, Japan

Free time

11:30 a.m.-4 p.m.

Plenary Session 9: Novel Clinical Trials Platforms

4-5:30 p.m. | Monarchy 1-4

  • 4 p.m. | Repurposing JNK inhibitors: A new path to target cancer through modulation of the tumor microenvironment
    Naoto T. Ueno, University of Hawaii Cancer Center, Honolulu, Hawaii
  • 4:25 p.m. | Combined inhibition of MEK and HDACs improves the cytotoxicity of CD4 and CD8 T cells in NRAS;ASXL1-driven acute myeloid leukemia mice*
    Jing Zhang, University of Wisconsin-Madison, Madison, Wisconsin
  • 4:50 p.m. | Title to be announced
    Takashi Owa, Eisai Inc., Nutley, New Jersey
  • 5:15 p.m. | DXd ADCs, emerging anti-cancer therapeutics with potent efficacy and manageable safety
    Naoya Harada, Daiichi Sankyo, Tokyo, Japan

Poster Session C

5:30-7:30 p.m. | Monarchy 5-7

Wednesday, February 5

Continental Breakfast and “Networking Roundtables”

7-8 a.m. | Grand Promenade

Plenary Session 10: Novel Roles of RNA in Cancer

8-9:30 a.m. | Monarchy 1-4    

  • 8 a.m. | Targeting epigenetic aberrations in the cancer microenvironment
    Akiko Takahashi, Japanese Foundation for Cancer Research, Tokyo, Japan
  • 8:25 a.m. | Harnessing mRNA splicing and stability for cancer treatment
    Akihide Yoshimi, National Cancer Center Japan, Tokyo, Japan
  • 8:50 a.m. | Title to be announced
    Adrian R. Krainer, Cold Spring Harbor Laboratory, Colder Spring Harbor, New York
  • 9:15 a.m. | PMR-116, a second generation RNA Polymerase I inhibitor*
    Luc Furic, Peter MacCallum Cancer Centre, Melbourne, Australia

Break

9:30-10 a.m. | Grand Promenade         

Plenary Session 11: Data Science

 10-11:30 a.m. | Monarchy 1-4

  • 10 a.m. | The surprisingly complex data science journey of clinical trial matching: Navigating challenges and uncovering opportunities
    Benjamin Haibe-Kains, University of Toronto, Toronto, Ontario, Canada
  • 10:25 a.m. | Title to be announced
    Jorge S. Reis-Filho, AstraZeneca, Gaithersburg, Maryland
  • 10:50 a.m. | Title to be announced
    Shumpei Ishikawa, University of Tokyo, Tokyo, Japan
  • 11:15 a.m. | Estimating divergence times of founder mutations in cancer predisposition genes in the Japanese population using shared haplotype regions*
    Wataru Nakamura, National Cancer Center Research Institute, Tokyo, Japan

free time

11:30 a.m.-4 p.m.

Plenary Session 12: Novel Immunotherapies

4-5:30 p.m. | Monarchy 1-4

  • 4 p.m. | Title to be announced
    Aude G. Chapuis, Fred Hutchinson Cancer Center, Seattle, Washington
  • 4:25 p.m. | Understanding T-cell and tumor cell molecular mechanisms of CAR T-cell therapy failure
    Yuki Kagoya, Keio University School of Medicine, Tokyo, Japan
  • 4:50 p.m. | Title to be announced
    Todd A. Fehniger, Washington University in St. Louis, St. Louis, Missouri
  • 5:15 p.m. | KROS 101: A next-generation GITR agonist boosting anti-tumor T cell responses and reprogramming the tumor microenvironment*
    Tesfahun Admasu, Cedars Sinai Medical Center, Los Angeles, California

Poster Session D

5:30-7:30 p.m. | Monarchy 5-7      

*Short talk from proffered abstract